Last reviewed · How we verify
Imatinib maintenance
Imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases to prevent cancer cell proliferation.
Imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases to prevent cancer cell proliferation. Used for Chronic myeloid leukemia (CML) maintenance therapy, Gastrointestinal stromal tumor (GIST) maintenance therapy.
At a glance
| Generic name | Imatinib maintenance |
|---|---|
| Also known as | Glivec, Imatinib mésilate |
| Sponsor | Centre Leon Berard |
| Drug class | Tyrosine kinase inhibitor |
| Target | BCR-ABL |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Imatinib selectively inhibits the BCR-ABL fusion protein tyrosine kinase, which is constitutively active in chronic myeloid leukemia (CML) and drives uncontrolled cell division. By blocking this kinase activity, imatinib induces apoptosis in leukemic cells and restores normal hematopoiesis. Maintenance therapy with imatinib is used to sustain remission and prevent relapse in patients who have achieved response.
Approved indications
- Chronic myeloid leukemia (CML) maintenance therapy
- Gastrointestinal stromal tumor (GIST) maintenance therapy
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Fatigue
- Muscle cramps
- Rash
- Fluid retention/edema
- Myelosuppression
Key clinical trials
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML (PHASE2)
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients (PHASE2)
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment (PHASE3)
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia (PHASE3)
- Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (PHASE2)
- Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |